J. R. Temerozo

This study shows that atazanavir inhibits SARS-CoV-2 Mpro, effectively reducing replication of both B.1 and gamma variants in vitro and in vivo.

This study shows apixaban inhibits SARS-CoV-2 replication by targeting its Mpro protease non-competitively, with higher potency than boceprevir.

This paper shows mefloquine inhibits SARS-CoV-2 infection in relevant cells more effectively than chloroquine without promoting viral mutations.

This study identifies HCV NS5A inhibitors as SARS-CoV-2 exonuclease inhibitors and shows synergy in combination with polymerase inhibitors to enhance antiviral efficacy.

This study evaluates a murine model using MHV-3 to mimic COVID-19 pathogenesis and tests TNF inhibition as a therapeutic strategy.

This study examines the effects of the cannabinoid agonist WIN 55,212-2 on inflammation and cell survival in human iPSC-derived cardiomyocytes infected with SARS-CoV-2, finding reduced cytokine levels and cytotoxic damage.

This study shows that inhibiting the Sigma-1 receptor with NE-100 reduces SARS-CoV-2 infection in human cardiomyocytes but also impairs cytoskeleton and contractility.

This study shows that atazanavir inhibits SARS-CoV-2 replication and reduces pro-inflammatory cytokine production in vitro.

This study shows that lipid droplets support SARS-CoV-2 replication and inflammatory mediator production, with DGAT-1 inhibition reducing viral replication and inflammation.

The paper shows elevated VIP plasma levels in severe COVID-19 patients correlate with survival and protective effects against SARS-CoV-2 in vitro.

This study evaluates the antiviral activity of daclatasvir and sofosbuvir against SARS-CoV-2 in vitro, showing inhibition of viral replication and associated pathologies.